Marjolein de Bruin-Weller

Nov 7, 2024 | emjreviews.com | Melinda Gooderham |Marjolein de Bruin-Weller |April W. Armstrong

While for some individuals with atopic dermatitis (AD), the disease can be controlled with topical treatments, those with moderate-to-severe AD often require systemic therapy for long-term disease control. Systemic treatments for AD include conventional systemic agents, small molecule inhibitors, and biologics, each with its own risks and benefits. For example, conventional systemic agents carry significant risks with long-term use, and small molecule inhibitors require frequent dosing.

Oct 22, 2023 | bpno.dk | Marjolein de Bruin-Weller

oktober 2023 At EADV 2023, dermatologist Marjolein de Bruin-Weller discusses new developments in atopic dermatitis treatment, including the approval of the IL-13 inhibitor lebrikizumab and the study of OX40 inhibitors. Long-term safety data on dupilumab and tralokinumab are presented, and new topical treatments, such as JAK inhibitors and PDE4 inhibitors, are emerging.